CSPC Pharma (01093) Surges Over 5% as Clinical Study Results of Co-Developed Anituzumab Published in Annals of Oncology

Stock News

Jan 28

CSPC PHARMA (01093) rose more than 5%. As of the time of writing, the stock was up 5.14%, trading at HK$10.44, with a turnover of HK$499 million. According to an announcement on CSPC Pharma's official WeChat account, the results of a Phase III clinical study for Anituzumab (KN026), co-developed by CSPC Pharma and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., targeting patients with HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma, have been successfully published in the top-tier oncology journal Annals of Oncology (Impact Factor: 65.4). This study was a randomized, double-blind, controlled, multi-center Phase III clinical trial designed to evaluate the efficacy and safety of Anituzumab combined with chemotherapy compared to standard treatment in HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma patients who had previously failed first-line treatment containing trastuzumab.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1195231383"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195231383\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195231383?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195231383","market":"fut","top_or_hot":-1,"title":"CSPC Pharma (01093) Surges Over 5% as Clinical Study Results of Co-Developed Anituzumab Published in Annals of Oncology","media":"Stock News","content":"<p>CSPC PHARMA (01093) rose more than 5%. As of the time of writing, the stock was up 5.14%, trading at HK$10.44, with a turnover of HK$499 million.\nAccording to an announcement on CSPC Pharma's official WeChat account, the results of a Phase III clinical study for Anituzumab (KN026), co-developed by CSPC Pharma and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., targeting patients with HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma, have been successfully published in the top-tier oncology journal Annals of Oncology (Impact Factor: 65.4).\nThis study was a randomized, double-blind, controlled, multi-center Phase III clinical trial designed to evaluate the efficacy and safety of Anituzumab combined with chemotherapy compared to standard treatment in HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma patients who had previously failed first-line treatment containing trastuzumab.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma (01093) Surges Over 5% as Clinical Study Results of Co-Developed Anituzumab Published in Annals of Oncology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma (01093) Surges Over 5% as Clinical Study Results of Co-Developed Anituzumab Published in Annals of Oncology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-28 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC PHARMA (01093) rose more than 5%. As of the time of writing, the stock was up 5.14%, trading at HK$10.44, with a turnover of HK$499 million.\nAccording to an announcement on CSPC Pharma's official WeChat account, the results of a Phase III clinical study for Anituzumab (KN026), co-developed by CSPC Pharma and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., targeting patients with HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma, have been successfully published in the top-tier oncology journal Annals of Oncology (Impact Factor: 65.4).\nThis study was a randomized, double-blind, controlled, multi-center Phase III clinical trial designed to evaluate the efficacy and safety of Anituzumab combined with chemotherapy compared to standard treatment in HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma patients who had previously failed first-line treatment containing trastuzumab.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1993786604.SGD","symbol_name":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","start_time":0,"source_url":"","article_id":"1195231383","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195231383","pubTimestamp":1769565178,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC PHARMA (01093) rose more than 5%. As of the time of writing, the stock was up 5.14%, trading at HK$10.44, with a turnover of HK$499 million. According to an announcement on CSPC Pharma's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","BK1521":"挪威政府全球养老基金持仓","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","01093":"石药集团","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","BK1191":"制药","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","BK1515":"抗疫概念","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC"},"translate_title":"联合开发的阿尼妥珠单抗临床研究结果发表在Annals of Oncology，石药集团(01093)大涨超5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC PHARMA (01093) rose more than 5%. As of the time of writing, the stock was up 5.14%, trading at HK$10.44, with a turnover of HK$499 million.\nAccording to an announcement on CSPC Pharma's official WeChat account, the results of a Phase III clinical study for Anituzumab (KN026), co-developed by CSPC Pharma and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., targeting patients with HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma, have been successfully published in the top-tier oncology journal Annals of Oncology (Impact Factor: 65.4).\nThis study was a randomized, double-blind, controlled, multi-center Phase III clinical trial designed to evaluate the efficacy and safety of Anituzumab combined with chemotherapy compared to standard treatment in HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma patients who had previously failed first-line treatment containing trastuzumab.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}